Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000548.5(TSC2):c.251C>T(p.Ala84Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000325 in 1,588,838 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A84T) has been classified as Benign.
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Computational evidence support a benign effect (MetaRNN=0.031080723).
BP6
Variant 16-2053367-C-T is Benign according to our data. Variant chr16-2053367-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 49212.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Uncertain_significance=1, not_provided=2, Benign=7}. Variant chr16-2053367-C-T is described in Lovd as [Benign].
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Aug 23, 2016
Variant summary: The TSC2 c.251C>T (p.Ala84Val) variant involves the alteration of a conserved nucleotide. 2/4 in silico tools predict a benign outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 20/32398 control chromosomes, predominantly observed in the European (Non-Finnish) and South Asian subpopulations at a frequency of 0.0008709 (14/16076) and 0.000704 (6/8528), respectively. This frequencies is about 10-13 times the estimated maximal expected allele frequency of a pathogenic TSC2 variant (0.0000688), suggesting this is likely a benign polymorphism found primarily in these two subpopulations. Co-occurrence of the variant of interest and a potential pathogenic TSC1 variant (c.1112T>G/p.Tyr297X) has been reported in one TSC patient. In addition, multiple clinical diagnostic laboratories classified this variant as likely benign. Taken together, this variant is classified as benign. -
Likely benign, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
Jul 01, 2024
TSC2: BP4 -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Nov 26, 2019
This variant is associated with the following publications: (PMID: 11208653, 28873162, 23514105) -
Benign, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Feb 04, 2011
- -
Tuberous sclerosis 2 Benign:4
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Nov 07, 2021
- -
Benign, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 30, 2024
- -
Benign, criteria provided, single submitter
clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Jul 07, 2023
- -
Likely benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Aug 31, 2022
- -
Tuberous sclerosis syndrome Uncertain:1Other:1
not provided, no classification provided
curation
Tuberous sclerosis database (TSC2)
-
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Jul 10, 2018
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitter
curation
Sema4, Sema4
Feb 13, 2021
- -
Likely benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Mar 04, 2022
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
not specified Benign:1
Benign, no assertion criteria provided
clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center